Arrowstreet Capital Limited Partnership Has $80.64 Million Holdings in Doximity, Inc. (NASDAQ:DOCS)

Arrowstreet Capital Limited Partnership raised its position in Doximity, Inc. (NASDAQ:DOCS) by 708.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,510,416 shares of the company’s stock after purchasing an additional 1,323,634 shares during the period. Arrowstreet Capital Limited Partnership owned 0.81% of Doximity worth $80,641,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. QSV Equity Investors LLC lifted its holdings in Doximity by 0.3% in the fourth quarter. QSV Equity Investors LLC now owns 60,763 shares of the company’s stock valued at $3,244,000 after buying an additional 186 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Doximity by 0.7% during the 4th quarter. Handelsbanken Fonder AB now owns 29,700 shares of the company’s stock valued at $1,586,000 after acquiring an additional 200 shares during the period. UMB Bank n.a. boosted its stake in Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company’s stock worth $31,000 after acquiring an additional 235 shares in the last quarter. Fielder Capital Group LLC grew its holdings in Doximity by 4.5% in the fourth quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock worth $293,000 after purchasing an additional 235 shares during the period. Finally, Larson Financial Group LLC grew its holdings in Doximity by 49.4% in the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company’s stock worth $40,000 after purchasing an additional 250 shares during the period. 87.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on DOCS shares. Raymond James reissued an “outperform” rating and set a $83.00 price objective (up previously from $65.00) on shares of Doximity in a research report on Friday, February 7th. KeyCorp reduced their price objective on Doximity from $70.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Doximity in a research report on Friday, February 7th. Leerink Partners raised shares of Doximity from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $60.00 to $90.00 in a research report on Friday, February 7th. Finally, Canaccord Genuity Group upped their price objective on shares of Doximity from $60.00 to $71.00 and gave the stock a “hold” rating in a report on Friday, February 7th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Doximity has an average rating of “Moderate Buy” and a consensus target price of $64.22.

Doximity Stock Down 0.7 %

DOCS stock opened at $58.11 on Tuesday. The firm has a market cap of $10.85 billion, a PE ratio of 58.11, a P/E/G ratio of 4.10 and a beta of 1.34. The business has a 50 day moving average of $65.57 and a 200-day moving average of $54.69. Doximity, Inc. has a 12-month low of $22.96 and a 12-month high of $85.21.

Insiders Place Their Bets

In related news, Director Timothy S. Cabral sold 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company’s stock, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 37.40% of the company’s stock.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.